An observational study of glycemic control in canagliflozin treated patients

Current Medical Research and Opinion

Volumn 31, Issue 8, 2015, Pages 1479-1486

  Meckley, L M ^a   Miyasato, G ^a   Kokkotos, F ^a   Bumbaugh, J ^b   Bailey, R A ^c  

^a Trinity Partners LLC   (United States)

^b Inovalon Inc   (United States)

^c Janssen Scientific Affairs   (United States)

Author keywords

Aged; Diabetes mellitus type 2; Quality indicators health care; Sodium glucose co transporter 2 inhibitor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; BILE ACID SEQUESTRANT; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIABETIC PATIENT; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; ADOLESCENT; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE BLOOD LEVEL; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CANAGLIFLOZIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84940662761     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1047748     Document Type: Article

References (22)

1. National Diabetes Statistics Report, 2014. Centers for Disease Control, 2014. Available at: http://www. cdc. gov/diabetes/pubs/statsreport14/national-diabetesreport-web. pdf [Last accessed 22 October 2014]
2. American Diabetes Association. Economic costs of diabetes in the U. S. in 2012. Diabetes Care 2013;36:1033-46
3. Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 2013;45: 253-61
4. Leading Causes of Death. Centers for Disease Control, 2014. Available at: http://www. cdc. gov/nchs/fastats/leading-causes-of-death. htm [Last accessed 17 November 2014]
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
6. National Committee for Quality Assurance (NCQA). HEDIS 2013: Technical Specifications for Health Plans. Washington, DC: National Committee for Quality Assurance, 2012
7. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-15
8. Bode B, Stenlö f K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) 2013;41:72-84
9. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, doubleblind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
10. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
11. Stenlö f K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
12. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
13. Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70:1149-58
14. Janssen Pharmaceuticals Inc. Invokana [package insert]. Titusville, NJ, 2014
15. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
16. Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry). Inovalon Inc., 2015. Available at: http://www. inovalon. com/howwehelp/more2-registry [Last accessed 20 February 2015]
17. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
18. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
19. American Diabetes Association. Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1):S5-13
20. Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014;14:37
21. Buysman EK, Chow W, Henk HJ, et al. Characteristics and shortterm outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin 2014;31:1-7
22. Schneeweiss S, Gagne JJ, Glynn RJ, et al. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 2011;90: 777-90